NASDAQ:ANIK

Anika Therapeutics (ANIK) Stock Forecast, Price & News

$18.63

-0.25 (-1.32%)

(As of 09/29/2023 ET)

Compare

Today's Range: $18.41
▼
$19.03
50-Day Range: $16.98
▼
$25.45
52-Week Range: $16.54
▼
$32.51

Volume: 113,383 shs
Average Volume: 121,779 shs
Market Capitalization: $272.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 26.1% Upside
$23.50 Price Target
Short Interest: Bearish
6.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.12
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.78) to ($0.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

799th out of 972 stocks

Surgical & Medical Instruments Industry

84th out of 101 stocks

3.3

Analyst's Opinion

Consensus Rating
Anika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.50, Anika Therapeutics has a forecasted upside of 26.1% from its current price of $18.63.
Amount of Analyst Coverage
Anika Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.83% of the float of Anika Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Anika Therapeutics has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Anika Therapeutics has recently increased by 21.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Anika Therapeutics does not currently pay a dividend.
Dividend Growth
Anika Therapeutics does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Anika Therapeutics has received a 38.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.
Environmental Sustainability
The Environmental Impact score for Anika Therapeutics is -2.12.

2.7

News and Social Media Coverage

News Sentiment
Anika Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Anika Therapeutics this week, compared to 3 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anika Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.85% of the stock of Anika Therapeutics is held by insiders.
Percentage Held by Institutions
90.79% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Anika Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anika Therapeutics is -12.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anika Therapeutics is -12.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anika Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Price History

30 days | 90 days | 365 days | Advanced Chart

ANIK Stock News Headlines

September 19, 2023 | finance.yahoo.com

Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting

September 16, 2023 | finanznachrichten.de

Anika Therapeutics Inc.: Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 29, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 1, 2023 | finance.yahoo.com

Down -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)

August 17, 2023 | finance.yahoo.com

Caligan Partners LP Boosts Stake in Anika Therapeutics Inc

August 17, 2023 | marketwatch.com

Anika Rotator-Cuff Treatment May Launch in 1Q Following Final FDA Approval

August 17, 2023 | finance.yahoo.com

Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

August 14, 2023 | msn.com

Barrington Research Upgrades Anika Therapeutics (ANIK)

September 29, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 11, 2023 | finance.yahoo.com

Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Intrinsic Value Is Potentially 92% Above Its Share Price

August 10, 2023 | msn.com

Stephens & Co. Maintains Anika Therapeutics (ANIK) Equal-Weight Recommendation

August 9, 2023 | finance.yahoo.com

Q2 2023 Anika Therapeutics Inc Earnings Call

August 9, 2023 | finanznachrichten.de

Anika Therapeutics Inc.: Anika Reports Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Advanced wound care market to grow by USD 4,020.97 million from 2022 to 2027|The increasing volume of surgical procedures drives growth - Technavio

July 12, 2023 | finance.yahoo.com

Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting

May 31, 2023 | msn.com

Stephens & Co. Reiterates Anika Therapeutics (ANIK) Equal-Weight Recommendation

May 30, 2023 | finance.yahoo.com

Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone

May 17, 2023 | marketwatch.com

Hemostatic Agents Market Research | 2023-2030

May 16, 2023 | finance.yahoo.com

Global Osteoarthritis Therapeutics Market to Reach $15.8 Billion by 2030

May 16, 2023 | seekingalpha.com

ANIK Anika Therapeutics, Inc.

May 15, 2023 | marketwatch.com

Injectable Hyaluronic Acid Fillers Market: 2023-2030 Revenue

May 12, 2023 | marketwatch.com

Hyaluronic Acid Products Market Price & News with Size Forecast

May 11, 2023 | marketwatch.com

2023 Arthritis Pain Injection Drug Market Size and Competitor Analysis in Medical Care Sector | with [104 Pages] and Forecast till 2031

May 11, 2023 | markets.businessinsider.com

Barrington Keeps Their Hold Rating on Anika Therapeutics (ANIK)

May 11, 2023 | marketwatch.com

2023-2029 Adhesion Barrier Gel Market Growth Prospects and Countries Analysis | with 85 Pages

May 10, 2023 | finanznachrichten.de

Anika Therapeutics Inc.: Anika Reports First Quarter 2023 Financial Results

May 9, 2023 | msn.com

Recap: Anika Therapeutics Q1 Earnings

See More Headlines

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Company Calendar

Last Earnings: 8/08/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:ANIK
CUSIP: 03525510
CIK: 898437
Web: www.anikatherapeutics.com
Phone: (781) 457-9000
Fax: 781-305-9720
Employees: 345
Year Founded: 1992

Price Target and Rating

Average Stock Price Forecast: $23.50
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +26.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,860,000.00
Net Margins: -13.68%
Pretax Margin: -16.56%
Return on Equity: -3.53%
Return on Assets: -2.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.49
Quick Ratio: 4.67

Sales & Book Value

Annual Sales: $156.24 million
Price / Sales: 1.74
Cash Flow: $0.49 per share
Price / Cash Flow: 37.72
Book Value: $19.55 per share
Price / Book: 0.95

Miscellaneous

Outstanding Shares: 14,630,000
Free Float: 13,775,000
Market Cap: $272.56 million
Optionable: Optionable
Beta: 0.78

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Cheryl Renee Blanchard Ph.D. (Age 59)
Pres, CEO & Director
Comp: $1.31M

Mr. Michael L. Levitz (Age 49)
Exec. VP, CFO & Treasurer
Comp: $710.6k

Mr. David Colleran J.D. (Age 51)
Exec. VP, Gen. Counsel & Corp. Sec.
Comp: $664.54k

Ms. Anne Nunes (Age 54)
Sr. VP & COO

Mr. Ian W. McLeod
VP & Chief Accounting Officer

Mr. Mark Namaroff (Age 60)
Exec. Director of Investor Relations & Corp. Communications

Mr. James Chase
Sr. VP of International Sales & Marketing

Mr. Ben Joseph
VP of Commercial & Corp. Devel.

Ms. Lisa Funiciello
VP of HR

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares.
View ANIK analyst ratings or view top-rated stocks.
What is Anika Therapeutics' stock price forecast for 2023?: 2 analysts have issued twelve-month price objectives for Anika Therapeutics' stock. Their ANIK share price forecasts range from $23.00 to $24.00. On average, they predict the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 26.1% from the stock's current price.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.
How have ANIK shares performed in 2023?: Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 37.1% and is now trading at $18.63.
View the best growth stocks for 2023 here.
When is Anika Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ANIK earnings forecast.
How were Anika Therapeutics' earnings last quarter?: Anika Therapeutics, Inc. (NASDAQ:ANIK) released its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.21. The biotechnology company had revenue of $44.30 million for the quarter, compared to analysts' expectations of $40.61 million. Anika Therapeutics had a negative net margin of 13.68% and a negative trailing twelve-month return on equity of 3.53%.
What guidance has Anika Therapeutics issued on next quarter's earnings?: Anika Therapeutics updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $159.50 million-$163.00 million, compared to the consensus revenue estimate of $161.84 million.

What other stocks do shareholders of Anika Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).
What is Anika Therapeutics' stock symbol?: Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How do I buy shares of Anika Therapeutics?: Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anika Therapeutics' stock price today?: One share of ANIK stock can currently be purchased for approximately $18.63.
How much money does Anika Therapeutics make?: Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $272.56 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.
How many employees does Anika Therapeutics have?: The company employs 345 workers across the globe.
How can I contact Anika Therapeutics?: Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial